世界の低ホスファターゼ症治療市場 – 2031 年までの業界動向と予測

请求目录 请求目录 与分析师交谈 与分析师交谈 立即购买 立即购买 购买前请咨询 提前咨询 免费样本报告 免费样本报告

世界の低ホスファターゼ症治療市場 – 2031 年までの業界動向と予測

  • Medical Devices
  • Published Report
  • Jun 2024
  • Global
  • 350 页面
  • 桌子數: 205
  • 图号: 42

Global Hypophosphatasia Treatment Market

市场规模(十亿美元)

CAGR :  % Diagram

Diagram Forecast Period
2024 –2031
Diagram Market Size (Base Year)
USD 1,329.26 Million
Diagram Market Size (Forecast Year)
USD 1,812.12 Million
Diagram CAGR
%
Diagram Major Markets Players
  • AstraZeneca
  • Pfizer Inc.
  • Abbott
  • Novartis AG
  • Be Biopharma

>世界の低ホスファターゼ症治療市場、タイプ別(歯性低ホスファターゼ症、偽性低ホスファターゼ症、その他)、治療タイプ別(酵素補充療法および支持療法)、投与経路別(注射および経口)、エンドユーザー別(病院、専門クリニック、その他)、流通チャネル別(病院薬局、小売薬局、オンライン薬局) - 2031年までの業界動向および予測。

低ホスファターゼ症治療市場

低ホスファターゼ症治療市場の分析と規模

アストラゼネカが2024年5月に発表した報告書によると、同社は疫学的に低ホスファターゼ症(HPP)の患者数は米国で6,000人未満であると推定しており、希少疾患としての地位を強調しています。この希少性は、満たされていない医療ニーズが大きく、集中的な治療開発の可能性を特徴とする低ホスファターゼ症市場の重要な推進力となっています。

低ホスファターゼ症治療市場低ホスファターゼ症治療市場

NORD(全米希少疾患協会)が2021年2月に発表した記事によると、低ホスファターゼ症(HPP)は、遺伝的に均質なこの集団内で特定の突然変異の発生率が高いなどの遺伝的要因により、カナダのメノナイト集団で最も多く見られます。日本では、遺伝的素因と、おそらくより効果的なスクリーニングと診断の実践の両方が有病率の高さに起因しており、HPP症例のより適切な特定と報告につながっています。

データブリッジマーケットリサーチは、世界の低ホスファターゼ症治療市場は、2023年の13億2,926万米ドルから2031年には18億1,212万米ドルに達し、2024年から2031年の予測期間に4.4%のCAGRで成長すると分析しています。

レポートメトリック

詳細

予測期間

2024年から2031年

基準年

2023

歴史的な年

2022 (2016~2021年にカスタマイズ可能)

定量単位

収益(百万米ドル)

対象セグメント

タイプ(歯性低ホスファターゼ症、偽性低ホスファターゼ症、その他)、治療タイプ(酵素補充療法および支持療法)、投与経路(注射および経口)、エンドユーザー(病院、専門クリニック、その他)、流通チャネル(病院薬局、小売薬局、オンライン薬局)

対象国

米国、カナダ、メキシコ、ドイツ、英国、フランス、イタリア、オランダ、スペイン、ロシア、スイス、トルコ、ベルギー、その他のヨーロッパ諸国、中国、日本、インド、韓国、オーストラリア、シンガポール、タイ、インドネシア、マレーシア、フィリピン、その他のアジア太平洋諸国、ブラジル、アルゼンチン、その他の南米諸国、サウジアラビア、UAE、イスラエル、南アフリカ、エジプト、その他の中東およびアフリカ諸国

対象となる市場プレーヤー

アストラゼネカ、ファイザー、アボット、ノバルティス、ビー・バイオファーマ、ピュレック、ラリーバイオ、ラムパート・バイオサイエンス、AM-ファーマBV、ロイヴァント・サイエンシズなど

市場の定義

低ホスファターゼ症 (HPP) は、骨や歯の石灰化障害を特徴とする、まれな遺伝性代謝障害です。この疾患は、アルカリホスファターゼ酵素をコードする ALPL 遺伝子の変異によって引き起こされます。アルカリホスファターゼは、石灰化プロセスに不可欠で、骨や歯へのカルシウムとリン酸の沈着を促進します。低ホスファターゼ症の重症度は、幼児期に発症し呼吸器合併症や早期死亡につながることが多い重症型から、成人期に早期歯喪失、骨痛、骨折などの症状を呈して発症する軽症型まで、幅広く異なります。

世界の低ホスファターゼ症治療市場の動向

このセクションでは、市場の推進要因、機会、制約、課題について理解します。これらについては、以下で詳しく説明します。      

ドライバ

  • 低ホスファターゼ症の発症率の増加

低ホスファターゼ症 (HPP) の発症率と疫学の上昇は、この希少疾患の治療における市場成長の重要な原動力です。HPP は、アルカリホスファターゼと呼ばれる酵素のレベルが低いために骨と歯が適切に発達しない病気ですが、認知度が高まり診断技術が向上するにつれて、診断される頻度が高まっています。発症率の上昇は、より多くの人々が治療オプションを求めていることを意味し、製薬会社が新しい治療法の研究開発に投資するきっかけとなっています。医療従事者と患者の両方が、生活の質を改善し、この困難な病気に関連する症状を管理するための効果的な介入の必要性を認識しているため、HPP 治療の市場は急速に拡大しています。

拘束

  • 治療費の高騰

HPPの主な治療である酵素補充療法は、年間数十万ドルの費用がかかる可能性があり、多くの患者が利用できません。この法外な費用は、特に包括的な健康保険や経済的手段を持たない患者の間で患者へのアクセスを制限し、保険に加入している患者でさえも多額の自己負担につながります。医療制度と患者の家族への経済的負担は計り知れず、必要な治療を断念するという難しい決断につながることがよくあります。この経済的障壁は、製薬会社がHPPの新しい治療法の開発に投資するインセンティブも減らします。治療を受けられる患者の数が限られているため、市場は経済的に実行不可能であると認識されており、研究開発への投資を妨げています。

低ホスファターゼ症治療市場

機会

  • さまざまな先進的治療法の導入増加

継続的な研究開発の取り組みにより、酵素補充療法、遺伝子治療、低分子薬など、HPP (低ホスファターゼ症) の新しい治療オプションが開発されています。これらの進歩には、酵素補充療法、遺伝子治療、または病気に関係する特定の経路を標的とする低分子薬が含まれます。これらのイノベーションに投資する企業は、大きな市場シェアを獲得する立場にあります。

チャレンジ

  • 薬物治療の中止の影響と関連する副作用

薬物治療の中止とそれに関連する副作用の影響は、世界の低ホスファターゼ症治療市場の成長にとって大きな課題となります。患者が副作用、有効性の低い認識、または非遵守のために治療を中止すると、病気の管理が妨げられるだけでなく、既存の治療の需要も減少します。これにより、市場の信頼が低下し、新しい治療法の規制承認が妨げられ、代替治療の出現が促進される可能性があります。さらに、医療介入を必要とする副作用は、医療費を増大させ、リソースを圧迫し、治療費の償還とアクセスに影響を与える可能性があります。これらの課題を克服するには、より安全で効果的な治療法の開発が必要であり、強力な患者教育とサポートは、市場の成長と持続可能性の課題として機能します。

最近の動向

  • 2024年1月、AM-Pharma BVは、心臓手術関連腎障害(CSA-RD)を予防するためにイロフォターゼアルファを投与する最初の患者を対象とした第2相臨床試験を開始しました。これは、化合物の潜在性を検証し、開発を進めるための重要なステップであり、最終的には治療用途と市場範囲を拡大することで同社に利益をもたらします。
  • 2023年10月、AM-Pharma BVは、成人低ホスファターゼ症(HPP)患者の潜在的な酵素補充療法としてのイロフォターゼアルファの第1b相臨床試験で良好な結果を報告しました。このマイルストーンは、化合物の有効性と安全性を実証し、市場と治療用途を拡大し、同社の成長と発展に利益をもたらす可能性があります。
  • 2023年9月、AM-Pharma BVはイロフォターゼアルファの臨床戦略を更新し、この化合物を心臓手術関連腎障害(CSA-RD)の予防治療および低ホスファターゼ症(HPP)の酵素補充療法として使用することを目指しています。これらの開発により、同社の市場と治療機会が大幅に拡大する可能性があります。
  • 2021年7月、アストラゼネカはアレクシオン・ファーマシューティカルズの買収を完了し、希少疾患治療薬への参入を果たしました。この買収により、免疫学におけるアストラゼネカの科学的プレゼンスが強化され、アレクシオンの補体生物学プラットフォームとパイプラインを活用して、希少疾患治療における継続的なイノベーションが可能になります。この買収は、希少疾患患者の満たされていない医療ニーズに対応し、アストラゼネカにとって大きな成長の機会となります。

世界の低ホスファターゼ症治療市場の範囲

世界の低ホスファターゼ症治療市場は、種類、治療の種類、投与経路、エンドユーザー、流通チャネルに基づいて 5 つの主要なセグメントに分割されています。セグメント間の成長は、ニッチな成長分野と市場へのアプローチ戦略を分析し、コア アプリケーション領域とターゲット市場の違いを判断するのに役立ちます。

タイプ

  • 歯周低ホスファターゼ症
  • 偽性低ホスファターゼ症
  • その他

タイプに基づいて、世界の低ホスファターゼ症治療市場は、歯性低ホスファターゼ症、偽性低ホスファターゼ症、その他に分類されます。

治療の種類

  • 酵素補充療法
  • 支持療法

治療の種類に基づいて、世界の低ホスファターゼ症治療市場は、酵素補充療法と支持療法に分類されます。

投与経路

  • 注射可能
  • オーラル

投与経路に基づいて、世界の低ホスファターゼ症治療市場は注射剤と経口剤に分類されます。

エンドユーザー

  • 病院
  • 専門クリニック
  • その他

エンドユーザーに基づいて、世界の低ホスファターゼ症治療市場は、病院、専門クリニック、その他に分類されます。

流通チャネル

  • 病院薬局
  • 小売薬局
  • オンライン薬局

流通チャネルに基づいて、世界の低ホスファターゼ症治療市場は、病院薬局、小売薬局、オンライン薬局に分類されます。

低ホスファターゼ症治療市場

世界の低ホスファターゼ症治療市場の地域分析/洞察

世界の低ホスファターゼ症治療市場は、種類、治療の種類、投与経路、エンドユーザー、流通チャネルに基づいて 5 つの主要なセグメントに分類されます。

この世界的な低ホスファターゼ症治療市場レポートで取り上げられている国は、米国、カナダ、メキシコ、ドイツ、英国、フランス、イタリア、オランダ、スペイン、ロシア、スイス、トルコ、ベルギー、その他のヨーロッパ諸国、中国、日本、インド、韓国、オーストラリア、シンガポール、タイ、インドネシア、マレーシア、フィリピン、その他のアジア太平洋諸国、ブラジル、アルゼンチン、その他の南米諸国、サウジアラビア、UAE、イスラエル、南アフリカ、エジプト、その他の中東およびアフリカ諸国です。

北米は、医療インフラが十分に整備されているため、世界の低ホスファターゼ症治療市場を支配すると予想されています。低ホスファターゼ症の有病率の高さ、希少疾患に対する認識の高さ、先進的な治療オプションの利用可能性、主要な市場プレーヤーの存在、および地域における継続的な研究開発活動により、米国は北米の低ホスファターゼ症治療市場を支配すると予想されています。

中国は、人口が多く、医療投資が増加し、疾患の認知度と診断率が向上しているため、アジア太平洋地域の低ホスファターゼ症治療市場で優位に立つと予想されています。さらに、成長を続ける同国の製薬業界は、専門的な治療薬の開発と流通を支えています。

ドイツは、先進的な技術の導入、強固な医療インフラ、成熟した市場により、ヨーロッパの低ホスファターゼ症治療市場で優位に立つと予想されています。

レポートの国別セクションでは、市場の現在および将来の傾向に影響を与える国内市場における個別の市場影響要因と規制の変更も提供しています。新規販売、交換販売、国の人口統計、規制行為、輸出入関税などのデータ ポイントは、各国の市場シナリオを予測するために使用される主要な指標の一部です。また、国別データの予測分析を提供する際には、グローバル ブランドの存在と可用性、地元および国内ブランドとの競争が激しいか少ないために直面​​する課題、販売チャネルの影響も考慮されます。

低ホスファターゼ症治療市場

競争環境と世界の低ホスファターゼ症治療市場シェア分析

世界の低ホスファターゼ症治療市場の競争状況は、競合他社の詳細を提供します。詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、生産拠点と施設、会社の強みと弱み、製品の発売、製品の承認、製品の幅と広さ、アプリケーションの優位性、および製品タイプのライフライン曲線が含まれます。上記のデータ ポイントは、会社の世界の低ホスファターゼ症治療市場への重点にのみ関連しています。

世界の低ホスファターゼ症治療市場で活動している主要な市場プレーヤーとしては、アストラゼネカ、ファイザー社、アボット、ノバルティスAG、ビー・バイオファーマ、ピュレック、ラリーバイオ、ラムパート・バイオサイエンス社、AM-ファーマBV、ロイヴァント・サイエンシズ社などが挙げられます。


SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

目录

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE GLOBAL HYPOPHOSPHATASIA TREATMENT MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 MULTIVARIATE MODELLING

2.7 MARKET APPLICATION COVERAGE GRID

2.8 PRODUCT LIFELINE CURVE

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTER’S FIVE FORCES

4.3 STRATEGIC DECISIONS

4.4 PATENT ANALYSIS

4.5 PRODUCT SALES BY YEAR

5 GLOBAL HYPOPHOSPHATASIA (HPP) TREATMENT MARKET: REGULATIONS

5.1 U.S. REGULATORY SCENARIO FOR HYPOPHOSPHATASIA (HPP) TREATMENT

5.2 EUROPE REGULATORY SCENARIO FOR HYPOPHOSPHATASIA (HPP) TREATMENT

5.3 INDIA

5.4 MIDDLE EAST AND AFRICA

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 INCREASING INCIDENCE RATE FOR HYPOPHOSPHATASIA

6.1.2 CONTINUOUS INCREASE IN CLINICAL TRIALS AND PIPELINE PRODUCTS

6.1.3 FAVOURABLE REIMBURSEMENT POLICIES

6.2 RESTRAINTS

6.2.1 HIGH COST OF TREATMENT

6.2.2 COMPLEX TREATMENT REGIMEN

6.3 OPPORTUNITIES

6.3.1 INCREASING ADOPTION OF VARIOUS TYPES OF ADVANCED THERAPY

6.3.2 INITIATIVES BY THE GOVERNMENT TO CREATE AWARENESS

6.4 CHALLENGES

6.4.1 IMPACT OF DISCONTINUATION OF DRUG TREATMENT AND RELATED ADVERSE EFFECT

6.4.2 GENETIC VARIABILITY AND DISEASE COMPLEXITY

7 GLOBAL HYPOPHOSPHATASIA TREATMENT MARKET, BY TYPES

7.1 OVERVIEW

7.2 ODONTOHYPOPHOSPHATASIA

7.3 PSEUDOHYPOPHOSPHATASIA

7.4 OTHERS

8 GLOBAL HYPOPHOSPHATASIA TREATMENT MARKET, BY THERAPY TYPE

8.1 OVERVIEW

8.2 ENZYME REPLACEMENT THERAPY

8.3 SUPPORTIVE THERAPY

9 GLOBAL HYPOPHOSPHATASIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

9.1 OVERVIEW

9.2 INJECTABLE

9.3 ORAL

10 GLOBAL HYPOPHOSPHATASIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL

10.1 OVERVIEW

10.2 HOSPITAL PHARMACY

10.3 RETAIL PHARMACY

10.4 ONLINE PHARMACY

11 GLOBAL HYPOPHOSPHATASIA TREATMENT MARKET, BY END USER

11.1 OVERVIEW

11.2 HOSPITALS

11.3 SPECIALTY CLINICS

11.4 OTHERS

12 GLOBAL HYPOPHOSPHATASIA TREATMENT MARKET, BY REGION

12.1 OVERVIEW

12.2 NORTH AMERICA

12.2.1 U.S.

12.2.2 CANADA

12.2.3 MEXICO

12.3 EUROPE

12.3.1 GERMANY

12.3.2 U.K.

12.3.3 FRANCE

12.3.4 ITALY

12.3.5 SPAIN

12.3.6 BELGIUM

12.3.7 RUSSIA

12.3.8 NETHERLANDS

12.3.9 TURKEY

12.3.10 SWITZERLAND

12.3.11 REST OF EUROPE

12.4 ASIA-PACIFIC

12.4.1 CHINA

12.4.2 INDIA

12.4.3 JAPAN

12.4.4 SOUTH KOREA

12.4.5 AUSTRALIA

12.4.6 SINGAPORE

12.4.7 MALAYSIA

12.4.8 INDONESIA

12.4.9 THAILAND

12.4.10 PHILIPPINES

12.4.11 REST OF ASIA-PACIFIC

12.5 MIDDLE EAST AND AFRICA

12.5.1 SOUTH AFRICA

12.5.2 SAUDI ARABIA

12.5.3 U.A.E.

12.5.4 EGYPT

12.5.5 ISRAEL

12.5.6 REST OF MIDDLE EAST AND AFRICA

12.6 SOUTH AMERICA

12.6.1 BRAZIL

12.6.2 ARGENTINA

12.6.3 REST OF SOUTH AMERICA

13 GLOBAL HYPOPHOSPHATASIA TREATMENT MARKET: COMPANY LANDSCAPE

13.1 COMPANY SHARE ANALYSIS: GLOBAL

13.2 COMPANY SHARE ANALYSIS: NORTH AMERICA

13.3 COMPANY SHARE ANALYSIS: EUROPE

13.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

14 SWOT ANALYSIS

15 COMPANY PROFILE

15.1 ASTRAZENECA

15.1.1 COMPANY SNAPSHOT

15.1.2 REVENUE ANALYSIS

15.1.3 COMPANY SHARE ANALYSIS

15.1.4 PRODUCT PORTFOLIO

15.1.5 RECENT DEVELOPMENT

15.2 PFIZER INC.

15.2.1 COMPANY SNAPSHOT

15.2.2 REVENUE ANALYSIS

15.2.3 COMPANY SHARE ANALYSIS

15.2.4 PRODUCT PORTFOLIO

15.2.5 RECENT DEVELOPMENTS

15.3 ABBOTT

15.3.1 COMPANY SNAPSHOT

15.3.2 REVENUE ANALYSIS

15.3.3 COMPANY SHARE ANALYSIS

15.3.4 PRODUCT PORTFOLIO

15.3.5 RECENT DEVELOPMENTS

15.4 NOVARTIS AG

15.4.1 COMPANY SNAPSHOT

15.4.2 REVENUE ANALYSIS

15.4.3 COMPANY SHARE ANALYSIS

15.4.4 PRODUCT PORTFOLIO

15.4.5 RECENT DEVELOPMENT

15.5 AM-PHARMA B.V.

15.5.1 COMPANY SNAPSHOT

15.5.2 COMPANY SHARE ANALYSIS

15.5.3 PRODUCT PORTFOLIO

15.5.4 RECENT DEVELOPMENT

15.6 BE BIOPHARMA

15.6.1 COMPANY SNAPSHOT

15.6.2 PRODUCT PORTFOLIO

15.6.3 RECENT DEVELOPMENT

15.7 PUREC.

15.7.1 COMPANY SNAPSHOT

15.7.2 PRODUCT PORTFOLIO

15.7.3 RECENT DEVELOPMENT

15.8 RALLYBIO

15.8.1 COMPANY SNAPSHOT

15.8.2 PRODUCT PORTFOLIO

15.8.3 RECENT DEVELOPMENTS

15.9 RAMPART BIOSCIENCE, INC.

15.9.1 COMPANY SNAPSHOT

15.9.2 PRODUCT PORTFOLIO

15.9.3 RECENT DEVELOPMENT

15.1 ROIVANT SCIENCES LTD.

15.10.1 COMPANY SNAPSHOT

15.10.2 PRODUCT PORTFOLIO

15.10.3 RECENT DEVELOPMENT

16 QUESTIONNAIRE

17 RELATED REPORTS

表格列表

TABLE 1 VARIOUS ASPECTS OF HYPOPHOSPHATASIA (HPP)

TABLE 2 TARGETED TREATMENT OF HYPOPHOSPHATASIA

TABLE 3 GLOBAL HYPOPHOSPHATASIA TREATMENT MARKET, BY TYPES, 2022-2031 (USD THOUSAND)

TABLE 4 GLOBAL ODONTOPHOSPHATASIA IN HYPOPHOSPHATASIA TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 5 GLOBAL PSEUDOPHOSPHATASIA IN HYPOPHOSPHATASIA TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 6 GLOBAL OTHERS IN HYPOPHOSPHATASIA TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 7 GLOBAL HYPOPHOSPHATASIA TREATMENT MARKET, BY THERAPY TYPE, 2022-2031 (USD THOUSAND)

TABLE 8 GLOBAL ENZYME REPLACEMENT THERAPY IN HYPOPHOSPHATASIA TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 9 GLOBAL SUPPORTIVE THERAPY IN HYPOPHOSPHATASIA TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 10 GLOBAL HYPOPHOSPHATASIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 11 GLOBAL INJECTABLE IN HYPOPHOSPHATASIA TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 12 GLOBAL ORAL IN HYPOPHOSPHATASIA TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 13 GLOBAL HYPOPHOSPHATASIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 14 GLOBAL HOSPITAL PHARMACY IN HYPOPHOSPHATASIA TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 15 GLOBAL RETAIL PHARMACY IN HYPOPHOSPHATASIA TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 16 GLOBAL ONLINE PHARMACY IN HYPOPHOSPHATASIA TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 17 GLOBAL HYPOPHOSPHATASIA TREATMENT MARKET, BY END-USER, 2022-2031 (USD THOUSAND)

TABLE 18 GLOBAL HOSPITALS IN HYPOPHOSPHATASIA TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 19 GLOBAL SPECIALTY CLINICS IN HYPOPHOSPHATASIA TREATMENTMARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 20 GLOBAL OTHERS IN HYPOPHOSPHATASIA TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 21 GLOBAL HYPOPHOSPHATASIA TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 22 NORTH AMERICA HYPOPHOSPHATASIA TREATMENT MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND )

TABLE 23 NORTH AMERICA HYPOPHOSPHATASIA TREATMENT MARKET, BY TYPES, 2022-2031 (USD THOUSAND )

TABLE 24 NORTH AMERICA HYPOPHOSPHATASIA TREATMENT MARKET, BY THERAPY TYPE, 2022-2031 (USD THOUSAND )

TABLE 25 NORTH AMERICA HYPOPHOSPHATASIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND )

TABLE 26 NORTH AMERICA HYPOPHOSPHATASIA TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND )

TABLE 27 NORTH AMERICA HYPOPHOSPHATASIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND )

TABLE 28 U.S. HYPOPHOSPHATASIA TREATMENT MARKET, BY TYPES, 2022-2031 (USD THOUSAND )

TABLE 29 U.S. HYPOPHOSPHATASIA TREATMENT MARKET, BY THERAPY TYPE, 2022-2031 (USD THOUSAND )

TABLE 30 U.S. HYPOPHOSPHATASIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND )

TABLE 31 U.S. HYPOPHOSPHATASIA TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND )

TABLE 32 U.S. HYPOPHOSPHATASIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND )

TABLE 33 CANADA HYPOPHOSPHATASIA TREATMENT MARKET, BY TYPES, 2022-2031 (USD THOUSAND )

TABLE 34 CANADA HYPOPHOSPHATASIA TREATMENT MARKET, BY THERAPY TYPE, 2022-2031 (USD THOUSAND )

TABLE 35 CANADA HYPOPHOSPHATASIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 36 CANADA HYPOPHOSPHATASIA TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND )

TABLE 37 CANADA HYPOPHOSPHATASIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND )

TABLE 38 MEXICO HYPOPHOSPHATASIA TREATMENT MARKET, BY TYPES, 2022-2031 (USD THOUSAND )

TABLE 39 MEXICO HYPOPHOSPHATASIA TREATMENT MARKET, BY THERAPY TYPE, 2022-2031 (USD THOUSAND )

TABLE 40 MEXICO HYPOPHOSPHATASIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND )

TABLE 41 MEXICO HYPOPHOSPHATASIA TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND )

TABLE 42 MEXICO HYPOPHOSPHATASIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND )

TABLE 43 EUROPE HYPOPHOSPHATASIA TREATMENT MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND )

TABLE 44 EUROPE HYPOPHOSPHATASIA TREATMENT MARKET, BY TYPES, 2022-2031 (USD THOUSAND )

TABLE 45 EUROPE HYPOPHOSPHATASIA TREATMENT MARKET, BY THERAPY TYPE, 2022-2031 (USD THOUSAND )

TABLE 46 EUROPE HYPOPHOSPHATASIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND )

TABLE 47 EUROPE HYPOPHOSPHATASIA TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND )

TABLE 48 EUROPE HYPOPHOSPHATASIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND )

TABLE 49 GERMANY HYPOPHOSPHATASIA TREATMENT MARKET, BY TYPES, 2022-2031 (USD THOUSAND )

TABLE 50 GERMANY HYPOPHOSPHATASIA TREATMENT MARKET, BY THERAPY TYPE, 2022-2031 (USD THOUSAND )

TABLE 51 GERMANY HYPOPHOSPHATASIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND )

TABLE 52 GERMANY HYPOPHOSPHATASIA TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND )

TABLE 53 GERMANY HYPOPHOSPHATASIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND )

TABLE 54 U.K. HYPOPHOSPHATASIA TREATMENT MARKET, BY TYPES, 2022-2031 (USD THOUSAND )

TABLE 55 U.K. HYPOPHOSPHATASIA TREATMENT MARKET, BY THERAPY TYPE, 2022-2031 (USD THOUSAND )

TABLE 56 U.K. HYPOPHOSPHATASIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND )

TABLE 57 U.K. HYPOPHOSPHATASIA TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND )

TABLE 58 U.K. HYPOPHOSPHATASIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND )

TABLE 59 FRANCE HYPOPHOSPHATASIA TREATMENT MARKET, BY TYPES, 2022-2031 (USD THOUSAND )

TABLE 60 FRANCE HYPOPHOSPHATASIA TREATMENT MARKET, BY THERAPY TYPE, 2022-2031 (USD THOUSAND )

TABLE 61 FRANCE HYPOPHOSPHATASIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND )

TABLE 62 FRANCE HYPOPHOSPHATASIA TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND )

TABLE 63 FRANCE HYPOPHOSPHATASIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND )

TABLE 64 ITALY HYPOPHOSPHATASIA TREATMENT MARKET, BY TYPES, 2022-2031 (USD THOUSAND )

TABLE 65 ITALY HYPOPHOSPHATASIA TREATMENT MARKET, BY THERAPY TYPE, 2022-2031 (USD THOUSAND )

TABLE 66 ITALY HYPOPHOSPHATASIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND )

TABLE 67 ITALY HYPOPHOSPHATASIA TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND )

TABLE 68 ITALY HYPOPHOSPHATASIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND )

TABLE 69 SPAIN HYPOPHOSPHATASIA TREATMENT MARKET, BY TYPES, 2022-2031 (USD THOUSAND )

TABLE 70 SPAIN HYPOPHOSPHATASIA TREATMENT MARKET, BY THERAPY TYPE, 2022-2031 (USD THOUSAND )

TABLE 71 SPAIN HYPOPHOSPHATASIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND )

TABLE 72 SPAIN HYPOPHOSPHATASIA TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND )

TABLE 73 SPAIN HYPOPHOSPHATASIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND )

TABLE 74 BELGIUM HYPOPHOSPHATASIA TREATMENT MARKET, BY TYPES, 2022-2031 (USD THOUSAND )

TABLE 75 BELGIUM HYPOPHOSPHATASIA TREATMENT MARKET, BY THERAPY TYPE, 2022-2031 (USD THOUSAND )

TABLE 76 BELGIUM HYPOPHOSPHATASIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND )

TABLE 77 BELGIUM HYPOPHOSPHATASIA TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND )

TABLE 78 BELGIUM HYPOPHOSPHATASIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND )

TABLE 79 RUSSIA HYPOPHOSPHATASIA TREATMENT MARKET, BY TYPES, 2022-2031 (USD THOUSAND )

TABLE 80 RUSSIA HYPOPHOSPHATASIA TREATMENT MARKET, BY THERAPY TYPE, 2022-2031 (USD THOUSAND )

TABLE 81 RUSSIA HYPOPHOSPHATASIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND )

TABLE 82 RUSSIA HYPOPHOSPHATASIA TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND )

TABLE 83 RUSSIA HYPOPHOSPHATASIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND )

TABLE 84 NETHERLANDS HYPOPHOSPHATASIA TREATMENT MARKET, BY TYPES, 2022-2031 (USD THOUSAND )

TABLE 85 NETHERLANDS HYPOPHOSPHATASIA TREATMENT MARKET, BY THERAPY TYPE, 2022-2031 (USD THOUSAND )

TABLE 86 NETHERLANDS HYPOPHOSPHATASIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND )

TABLE 87 NETHERLANDS HYPOPHOSPHATASIA TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND )

TABLE 88 NETHERLANDS HYPOPHOSPHATASIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND )

TABLE 89 TURKEY HYPOPHOSPHATASIA TREATMENT MARKET, BY TYPES, 2022-2031 (USD THOUSAND )

TABLE 90 TURKEY HYPOPHOSPHATASIA TREATMENT MARKET, BY THERAPY TYPE, 2022-2031 (USD THOUSAND )

TABLE 91 TURKEY HYPOPHOSPHATASIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND )

TABLE 92 TURKEY HYPOPHOSPHATASIA TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND )

TABLE 93 TURKEY HYPOPHOSPHATASIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND )

TABLE 94 SWITZERLAND HYPOPHOSPHATASIA TREATMENT MARKET, BY TYPES, 2022-2031 (USD THOUSAND )

TABLE 95 SWITZERLAND HYPOPHOSPHATASIA TREATMENT MARKET, BY THERAPY TYPE, 2022-2031 (USD THOUSAND )

TABLE 96 SWITZERLAND HYPOPHOSPHATASIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND )

TABLE 97 SWITZERLAND HYPOPHOSPHATASIA TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND )

TABLE 98 SWITZERLAND HYPOPHOSPHATASIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND )

TABLE 99 REST OF EUROPE HYPOPHOSPHATASIA TREATMENT MARKET, BY TYPES, 2022-2031 (USD THOUSAND )

TABLE 100 ASIA-PACIFIC HYPOPHOSPHATASIA TREATMENT MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)

TABLE 101 ASIA-PACIFIC HYPOPHOSPHATASIA TREATMENT MARKET, BY TYPES, 2022-2031 (USD THOUSAND)

TABLE 102 ASIA-PACIFIC HYPOPHOSPHATASIA TREATMENT MARKET, BY THERAPY TYPE, 2022-2031 (USD THOUSAND)

TABLE 103 ASIA-PACIFIC HYPOPHOSPHATASIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 104 ASIA-PACIFIC HYPOPHOSPHATASIA TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 105 ASIA-PACIFIC HYPOPHOSPHATASIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 106 CHINA HYPOPHOSPHATASIA TREATMENT MARKET, BY TYPES, 2022-2031 (USD THOUSAND)

TABLE 107 CHINA HYPOPHOSPHATASIA TREATMENT MARKET, BY THERAPY TYPE, 2022-2031 (USD THOUSAND)

TABLE 108 CHINA HYPOPHOSPHATASIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 109 CHINA HYPOPHOSPHATASIA TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 110 CHINA HYPOPHOSPHATASIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 111 INDIA HYPOPHOSPHATASIA TREATMENT MARKET, BY TYPES, 2022-2031 (USD THOUSAND)

TABLE 112 INDIA HYPOPHOSPHATASIA TREATMENT MARKET, BY THERAPY TYPE, 2022-2031 (USD THOUSAND)

TABLE 113 INDIA HYPOPHOSPHATASIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 114 INDIA HYPOPHOSPHATASIA TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 115 INDIA HYPOPHOSPHATASIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 116 JAPAN HYPOPHOSPHATASIA TREATMENT MARKET, BY TYPES, 2022-2031 (USD THOUSAND)

TABLE 117 JAPAN HYPOPHOSPHATASIA TREATMENT MARKET, BY THERAPY TYPE, 2022-2031 (USD THOUSAND)

TABLE 118 JAPAN HYPOPHOSPHATASIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 119 JAPAN HYPOPHOSPHATASIA TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 120 JAPAN HYPOPHOSPHATASIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 121 SOUTH KOREA HYPOPHOSPHATASIA TREATMENT MARKET, BY TYPES, 2022-2031 (USD THOUSAND)

TABLE 122 SOUTH KOREA HYPOPHOSPHATASIA TREATMENT MARKET, BY THERAPY TYPE, 2022-2031 (USD THOUSAND)

TABLE 123 SOUTH KOREA HYPOPHOSPHATASIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 124 SOUTH KOREA HYPOPHOSPHATASIA TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 125 SOUTH KOREA HYPOPHOSPHATASIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 126 AUSTRALIA HYPOPHOSPHATASIA TREATMENT MARKET, BY TYPES, 2022-2031 (USD THOUSAND)

TABLE 127 AUSTRALIA HYPOPHOSPHATASIA TREATMENT MARKET, BY THERAPY TYPE, 2022-2031 (USD THOUSAND)

TABLE 128 AUSTRALIA HYPOPHOSPHATASIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 129 AUSTRALIA HYPOPHOSPHATASIA TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 130 AUSTRALIA HYPOPHOSPHATASIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 131 SINGAPORE HYPOPHOSPHATASIA TREATMENT MARKET, BY TYPES, 2022-2031 (USD THOUSAND)

TABLE 132 SINGAPORE HYPOPHOSPHATASIA TREATMENT MARKET, BY THERAPY TYPE, 2022-2031 (USD THOUSAND)

TABLE 133 SINGAPORE HYPOPHOSPHATASIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 134 SINGAPORE HYPOPHOSPHATASIA TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 135 SINGAPORE HYPOPHOSPHATASIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 136 MALAYSIA HYPOPHOSPHATASIA TREATMENT MARKET, BY TYPES, 2022-2031 (USD THOUSAND)

TABLE 137 MALAYSIA HYPOPHOSPHATASIA TREATMENT MARKET, BY THERAPY TYPE, 2022-2031 (USD THOUSAND)

TABLE 138 MALAYSIA HYPOPHOSPHATASIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 139 MALAYSIA HYPOPHOSPHATASIA TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 140 MALAYSIA HYPOPHOSPHATASIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 141 INDONESIA HYPOPHOSPHATASIA TREATMENT MARKET, BY TYPES, 2022-2031 (USD THOUSAND)

TABLE 142 INDONESIA HYPOPHOSPHATASIA TREATMENT MARKET, BY THERAPY TYPES, 2022-2031 (USD THOUSAND)

TABLE 143 INDONESIA HYPOPHOSPHATASIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 144 INDONESIA HYPOPHOSPHATASIA TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 145 INDONESIA HYPOPHOSPHATASIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 146 THAILAND HYPOPHOSPHATASIA TREATMENT MARKET, BY TYPES, 2022-2031 (USD THOUSAND)

TABLE 147 THAILAND HYPOPHOSPHATASIA TREATMENT MARKET, BY THERAPY TYPE, 2022-2031 (USD THOUSAND)

TABLE 148 THAILAND HYPOPHOSPHATASIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 149 THAILAND HYPOPHOSPHATASIA TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 150 THAILAND HYPOPHOSPHATASIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 151 PHILIPPINES HYPOPHOSPHATASIA TREATMENT MARKET, BY TYPES, 2022-2031 (USD THOUSAND)

TABLE 152 PHILIPPINES HYPOPHOSPHATASIA TREATMENT MARKET, BY THERAPY TYPE, 2022-2031 (USD THOUSAND)

TABLE 153 PHILIPPINES HYPOPHOSPHATASIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 154 PHILIPPINES HYPOPHOSPHATASIA TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 155 PHILIPPINES HYPOPHOSPHATASIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 156 REST OF ASIA-PACIFIC HYPOPHOSPHATASIA TREATMENT MARKET, BY TYPES, 2022-2031 (USD THOUSAND)

TABLE 157 MIDDLE EAST AND AFRICA HYPOPHOSPHATASIA TREATMENT MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND )

TABLE 158 MIDDLE EAST AND AFRICA HYPOPHOSPHATASIA TREATMENT MARKET, BY TYPES, 2022-2031 (USD THOUSAND )

TABLE 159 MIDDLE EAST AND AFRICA HYPOPHOSPHATASIA TREATMENT MARKET, BY THERAPY TYPE, 2022-2031 (USD THOUSAND )

TABLE 160 MIDDLE EAST AND AFRICA HYPOPHOSPHATASIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND )

TABLE 161 MIDDLE EAST AND AFRICA HYPOPHOSPHATASIA TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND )

TABLE 162 MIDDLE EAST AND AFRICA HYPOPHOSPHATASIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND )

TABLE 163 SOUTH AFRICA HYPOPHOSPHATASIA TREATMENT MARKET, BY TYPES, 2022-2031 (USD THOUSAND )

TABLE 164 SOUTH AFRICA HYPOPHOSPHATASIA TREATMENT MARKET, BY THERAPY TYPE, 2022-2031 (USD THOUSAND )

TABLE 165 SOUTH AFRICA HYPOPHOSPHATASIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND )

TABLE 166 SOUTH AFRICA HYPOPHOSPHATASIA TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND )

TABLE 167 SOUTH AFRICA HYPOPHOSPHATASIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND )

TABLE 168 SAUDI ARABIA HYPOPHOSPHATASIA TREATMENT MARKET, BY TYPES, 2022-2031 (USD THOUSAND )

TABLE 169 SAUDI ARABIA HYPOPHOSPHATASIA TREATMENT MARKET, BY THERAPY TYPE, 2022-2031 (USD THOUSAND )

TABLE 170 SAUDI ARABIA HYPOPHOSPHATASIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND )

TABLE 171 SAUDI ARABIA HYPOPHOSPHATASIA TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND )

TABLE 172 SAUDI ARABIA HYPOPHOSPHATASIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND )

TABLE 173 U.A.E. HYPOPHOSPHATASIA TREATMENT MARKET, BY TYPES, 2022-2031 (USD THOUSAND )

TABLE 174 U.A.E. HYPOPHOSPHATASIA TREATMENT MARKET, BY THERAPY TYPE, 2022-2031 (USD THOUSAND )

TABLE 175 U.A.E. HYPOPHOSPHATASIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND )

TABLE 176 U.A.E. HYPOPHOSPHATASIA TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND )

TABLE 177 U.A.E. HYPOPHOSPHATASIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND )

TABLE 178 EGYPT HYPOPHOSPHATASIA TREATMENT MARKET, BY TYPES, 2022-2031 (USD THOUSAND )

TABLE 179 EGYPT HYPOPHOSPHATASIA TREATMENT MARKET, BY THERAPY TYPE, 2022-2031 (USD THOUSAND )

TABLE 180 EGYPT HYPOPHOSPHATASIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND )

TABLE 181 EGYPT HYPOPHOSPHATASIA TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND )

TABLE 182 EGYPT HYPOPHOSPHATASIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND )

TABLE 183 ISRAEL HYPOPHOSPHATASIA TREATMENT MARKET, BY TYPES, 2022-2031 (USD THOUSAND )

TABLE 184 ISRAEL HYPOPHOSPHATASIA TREATMENT MARKET, BY THERAPY TYPE, 2022-2031 (USD THOUSAND )

TABLE 185 ISRAEL HYPOPHOSPHATASIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND )

TABLE 186 ISRAEL HYPOPHOSPHATASIA TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND )

TABLE 187 ISRAEL HYPOPHOSPHATASIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND )

TABLE 188 REST OF MIDDLE EAST AND AFRICA HYPOPHOSPHATASIA TREATMENT MARKET, BY TYPES, 2022-2031 (USD THOUSAND )

TABLE 189 SOUTH AMERICA HYPOPHOSPHATASIA TREATMENT MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND )

TABLE 190 SOUTH AMERICA HYPOPHOSPHATASIA TREATMENT MARKET, BY TYPES, 2022-2031 (USD THOUSAND )

TABLE 191 SOUTH AMERICA HYPOPHOSPHATASIA TREATMENT MARKET, BY THERAPY TYPE, 2022-2031 (USD THOUSAND )

TABLE 192 SOUTH AMERICA HYPOPHOSPHATASIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND )

TABLE 193 SOUTH AMERICA HYPOPHOSPHATASIA TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND )

TABLE 194 SOUTH AMERICA HYPOPHOSPHATASIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND )

TABLE 195 BRAZIL HYPOPHOSPHATASIA TREATMENT MARKET, BY TYPES, 2022-2031 (USD THOUSAND )

TABLE 196 BRAZIL HYPOPHOSPHATASIA TREATMENT MARKET, BY THERAPY TYPE, 2022-2031 (USD THOUSAND )

TABLE 197 BRAZIL HYPOPHOSPHATASIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND )

TABLE 198 BRAZIL HYPOPHOSPHATASIA TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND )

TABLE 199 BRAZIL HYPOPHOSPHATASIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND )

TABLE 200 ARGENTINA HYPOPHOSPHATASIA TREATMENT MARKET, BY TYPES, 2022-2031 (USD THOUSAND )

TABLE 201 ARGENTINA HYPOPHOSPHATASIA TREATMENT MARKET, BY THERAPY TYPE, 2022-2031 (USD THOUSAND )

TABLE 202 ARGENTINA HYPOPHOSPHATASIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND )

TABLE 203 ARGENTINA HYPOPHOSPHATASIA TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND )

TABLE 204 ARGENTINA HYPOPHOSPHATASIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND )

TABLE 205 REST OF SOUTH AMERICA HYPOPHOSPHATASIA TREATMENT MARKET, BY TYPES, 2022-2031 (USD THOUSAND )

图片列表

FIGURE 1 GLOBAL HYPOPHOSPHATASIA TREATMENT MARKET: SEGMENTATION

FIGURE 2 GLOBAL HYPOPHOSPHATASIA TREATMENT MARKET: DATA TRIANGULATION

FIGURE 3 GLOBAL HYPOPHOSPHATASIA TREATMENT MARKET: DROC ANALYSIS

FIGURE 4 GLOBAL HYPOPHOSPHATASIA TREATMENT MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS

FIGURE 5 GLOBAL HYPOPHOSPHATASIA TREATMENT MARKET: COMPANY RESEARCH ANALYSIS.

FIGURE 6 GLOBAL HYPOPHOSPHATASIA TREATMENT MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 GLOBAL HYPOPHOSPHATASIA TREATMENT MARKET: MARKET APPLICATION COVERAGE GRID

FIGURE 8 GLOBAL HYPOPHOSPHATASIA TREATMENT MARKET: DBMR MARKET POSITION GRID

FIGURE 9 GLOBAL HYPOPHOSPHATASIA TREATMENT MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 GLOBAL HYPOPHOSPHATASIA TREATMENT MARKET: SEGMENTATION

FIGURE 11 SEGMENTS COMPRISE THE GLOBAL HYPOPHOSPHATASIA TREATMENT MARKET, BY TYPE

FIGURE 12 GLOBAL HYPOPHOSPHATASIA TREATMENT MARKET : EXECUTIVE SUMMARY

FIGURE 13 INCREASING DIAGNOSIS FOR HYPOPHOSPHATASIA IS DRIVING THE GROWTH OF THE GLOBAL HYPOPHOSPHATASIA TREATMENT MARKET FROM 2024 TO 2031

FIGURE 14 THE TYPES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL HYPOPHOSPHATASIA TREATMENT MARKET IN 2024 AND 2031

FIGURE 15 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL HYPOPHOSPHATASIA TREATMENT MARKET AND IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2024 TO 2031

FIGURE 16 ASIA-PACIFIC IS THE FASTEST-GROWING REGION FOR HYPOPHOSPHATASIA TREATMENT MARKET MANUFACTURERS IN THE FORECAST PERIOD OF 2024 TO 2031

FIGURE 17 DRIVERS, RESTRIANTS, OPPORTUNITIES, AND CHALLENGES OF HYPOPHOSPHATASIA TREATMENT MARKET

FIGURE 18 GLOBAL HYPOPHOSPHATASIA TREATMENT MARKET: BY TYPES, 2023

FIGURE 19 GLOBAL HYPOPHOSPHATASIA TREATMENT MARKET: BY TYPES, 2024-2031 (USD THOUSAND)

FIGURE 20 GLOBAL HYPOPHOSPHATASIA TREATMENT MARKET: BY TYPES, CAGR (2024-2031)

FIGURE 21 GLOBAL HYPOPHOSPHATASIA TREATMENT MARKET: BY TYPES, LIFELINE CURVE

FIGURE 22 GLOBAL HYPOPHOSPHATASIA TREATMENT MARKET: BY THEREPY TYPE, 2023

FIGURE 23 GLOBAL HYPOPHOSPHATASIA TREATMENT MARKET: BY THEREPY TYPE, 2024-2031 (USD THOUSAND)

FIGURE 24 GLOBAL HYPOPHOSPHATASIA TREATMENT MARKET: BY THEREPY TYPE, CAGR (2024-2031)

FIGURE 25 GLOBAL HYPOPHOSPHATASIA TREATMENT MARKET: BY THEREPY TYPE, LIFELINE CURVE

FIGURE 26 GLOBAL HYPOPHOSPHATASIA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2023

FIGURE 27 GLOBAL HYPOPHOSPHATASIA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2024-2031 (USD THOUSAND)

FIGURE 28 GLOBAL HYPOPHOSPHATASIA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2024-2031)

FIGURE 29 GLOBAL HYPOPHOSPHATASIA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 30 GLOBAL HYPOPHOSPHATASIA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2023

FIGURE 31 GLOBAL HYPOPHOSPHATASIA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD THOUSAND)

FIGURE 32 GLOBAL HYPOPHOSPHATASIA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)

FIGURE 33 GLOBAL HYPOPHOSPHATASIA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 34 GLOBAL HYPOPHOSPHATASIA TREATMENT MARKET: BY END USER, 2023

FIGURE 35 GLOBAL HYPOPHOSPHATASIA TREATMENT MARKET: BY END USER, 2024-2031 (USD THOUSAND)

FIGURE 36 GLOBAL HYPOPHOSPHATASIA TREATMENT MARKET: BY END USER, CAGR (2024-2031)

FIGURE 37 GLOBAL HYPOPHOSPHATASIA TREATMENT MARKET: BY END USER, LIFELINE CURVE

FIGURE 38 GLOBAL HYPOPHOSPHATASIA TREATMENT MARKET: SNAPSHOT (2023)

FIGURE 39 GLOBAL HYPOPHOSPHATASIA TREATMENT MARKET: COMPANY SHARE 2023 (%)

FIGURE 40 NORTH AMERICA HYPOPHOSPHATASIA TREATMENT MARKET: COMPANY SHARE 2023 (%)

FIGURE 41 EUROPE HYPOPHOSPHATASIA TREATMENT MARKET: COMPANY SHARE 2023 (%)

FIGURE 42 ASIA-PACIFIC HYPOPHOSPHATASIA TREATMENT MARKET: COMPANY SHARE 2023 (%)

查看详细信息 Right Arrow

研究方法

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

可定制

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

The market is segmented based on , By Types (Odontohypophosphatasia, Pseudohypophosphatasia, and Others), Therapy Type (Enzyme Replacement Therapy and Supportive Therapy), Route of Administration (Injectable and Oral), End User (Hospitals, Speciality Clinics, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) - Industry Trends and Forecast to 2031 . .
The Global Hypophosphatasia Treatment Market size was valued at USD 1329.26 USD Million in 2023.
The Global Hypophosphatasia Treatment Market is projected to grow at a CAGR of 4.4% during the forecast period of 2024 to 2031.
The major players operating in the market include AstraZeneca, Pfizer Inc., Abbott, Novartis AG, Be Biopharma, PuREC, Rallybio, Rampart Bioscience, Inc., AM-Pharma B.V., and Roivant Sciences Ltd. among others.
The market report covers data from the U.S., Canada, Mexico, Germany, U.K., France, Italy, Netherlands, Spain, Russia, Switzerland, Turkey, Belgium, rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Indonesia, Malaysia, Philippines, rest of Asia-Pacific, Brazil, Argentina, rest of South America, Saudi Arabia, U.A.E., Israel, South Africa, Egypt, and rest of Middle East and Africa.